Oxford Biomedica
Oxford, United Kingdom
Hybrid — also manufactures internal programs
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
76.2
Signal Score
○ FDA Inspections
✓ Clinical Trials (7)
○ SEC Filings
✓ Press (20)
✓ EMA GMP (4)
✓ MHRA GMP (8)
Quick Facts: Oxford Biomedica
- Signal Score
- 76.2/100 (as of 2026-09-07)
- Quality Compliance
- 100.0/100
- Headquarters
- Oxford, United Kingdom
- Website
- https://oxb.com
- Modalities
- Lentiviral, AAV, Plasmid DNA
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Oxford Biomedica
Pioneer in lentiviral vector manufacturing.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
100.0
FDA InspectionsNo US records on file
EMA GMP Certificates4 on record
MHRA GMP Certificates8 on record
Operations
58.6
Programs
— no verified data
Sponsors— no verified data
ModalitiesLentiviral, AAV, Plasmid DNA
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
NCT01856439
Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease
PHASE1/PHASE2
Terminated
Source: ClinicalTrials.gov · Retrieved Oct 07, 2026
Financial Stability
75.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
58.0
Capacity status: Available
StatusAvailable
Recent Press20 articles
Attribution not established
(2)
These records are excluded from this company’s established evidence
because their attribution is unresolved. This describes an evidence-linking
limitation, not an assessment of the underlying regulatory findings.
| Source | Establishment named by the regulator | Location | Identifier |
|---|---|---|---|
| MHRA GMP certificate | PET RADIOPHARMACY OXFORD (PROX) | OXFORD | — |
| MHRA GMP certificate | OXFORD BIOMEDICAL RESEARCH CENTRE | OXFORD | — |
Source records retained verbatim · attribution not established
Oxford Biomedica EMA GMP Compliance 4 certificates
2024-04
2023-09
2023-09
2020-12
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| 2024_HPF_FR_112 | Oxford Biomedica (France) S.A.S. | France | 2024-04-12 | COMPLIANT |
| 2024_HPF_FR_026_ND | Oxford Biomedica (France) S.A.S. | France | 2023-09-22 | COMPLIANT |
| 2024_HPF_FR_027_ND | Oxford Biomedica (France) S.A.S. | France | 2023-09-22 | COMPLIANT |
| 30363/IMP12861/001 | OxFord Biomedica (Ireland) Limited | Ireland | 2020-12-15 | NON-COMPLIANT |
Source: EMA EudraGMDP · Retrieved Oct 07, 2026
Oxford Biomedica MHRA GMP Compliance 8 certificates
2025-07
2025-07
2025-03
2025-03
2024-07
2024-07
2024-07
2024-07
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK MIA 17479 Insp GMP/IMP 17479/19229463-0008[H] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 2ZY | 2025-07-25 | COMPLIANT |
| UK MIA(IMP) 17479 Insp GMP/IMP 17479/19229463-0008[I] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 2ZY | 2025-07-25 | COMPLIANT |
| UK MIA 17479 Insp GMP/IMP 17479/12357407-0006[H] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX5 1QU | 2025-03-07 | COMPLIANT |
| UK MIA(IMP) 17479 Insp GMP/IMP 17479/12357407-0006[I] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX5 1QU | 2025-03-07 | COMPLIANT |
| UK MIA 17479 Insp GMP/IMP 17479/12551187-0008[H] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 6LT | 2024-07-23 | COMPLIANT |
| UK MIA(IMP) 17479 Insp GMP/IMP 17479/12551187-0008[I] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 6LT | 2024-07-23 | COMPLIANT |
| UK MIA(IMP) 17479 Insp GMP/IMP 17479/285627-0009[I] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 6LX | 2024-07-23 | COMPLIANT |
| UK MIA 17479 Insp GMP/IMP 17479/285627-0009[H] | OXFORD BIOMEDICA (UK) LIMITED | OXFORD OX4 6LX | 2024-07-23 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Oct 07, 2026
Clinical Activity 7 studies
NCT01856439
Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease
PHASE1/PHASE2
Terminated
NCT01301443
Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related...
PHASE1
Completed
NCT00627588
Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for...
PHASE1/PHASE2
Completed
NCT00397345
TroVax Renal Immunotherapy Survival Trial
PHASE3
Completed
NCT00445523
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients...
PHASE2
Completed
NCT00325507
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal...
PHASE2
Completed
NCT00083941
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of...
PHASE2
Completed
Source: ClinicalTrials.gov · Retrieved Oct 07, 2026
Recent News 20 articles
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development - The Globe and Mail
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development The Globe and Mail
Oxford Biomedica Launches Fast-track Viral Vector Manufacturing Service - DirectorsTalk Interviews
Oxford Biomedica Launches Fast-track Viral Vector Manufacturing Service DirectorsTalk Interviews
Oxford BioMedica accelerates viral vector development and manufacture - London South East
Oxford BioMedica accelerates viral vector development and manufacture London South East
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development - TipRanks
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development TipRanks
Oxford Biomedica Share News (OXB) - London South East
Oxford Biomedica Share News (OXB) London South East
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role - The Globe and Mail
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role The Globe and Mail
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role - TipRanks
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role TipRanks
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability - Bitget
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability Bitget
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability - Bitget
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability Bitget
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge - ca.investing.com
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge Investing.com Canada
Oxford BioMedica shares fall as warns on loss-making first half - London South East
Oxford BioMedica shares fall as warns on loss-making first half London South East
Earnings call transcript: Oxford Biomedica’s H2 2025 results show strong revenue growth - Investing.com
Earnings call transcript: Oxford Biomedica’s H2 2025 results show strong revenue growth Investing.com
Oxford Biomedica H2 Earnings Call Highlights - Yahoo Finance
Oxford Biomedica H2 Earnings Call Highlights Yahoo Finance
Oxford BioMedica Returns to Profit as U.S. Expansion and Big Pharma Deals Lift Outlook - TipRanks
Oxford BioMedica Returns to Profit as U.S. Expansion and Big Pharma Deals Lift Outlook TipRanks
Oxford BioMedica shares fall as warns on loss-making first half - marketscreener.com
Oxford BioMedica shares fall as warns on loss-making first half marketscreener.com
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge - Investing.com
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge Investing.com
Oxford Biomedica H2 Earnings Call Highlights - MarketBeat
Oxford Biomedica H2 Earnings Call Highlights MarketBeat
Earnings call transcript: Oxford Biomedica’s H2 2025 results show strong revenue growth - Investing.com
Earnings call transcript: Oxford Biomedica’s H2 2025 results show strong revenue growth Investing.com
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge By Investing.com - za.investing.com
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge By Investing.com za.investing.com
Oxford Biomedica resumed with a Buy at Jefferies - TipRanks
Oxford Biomedica resumed with a Buy at Jefferies TipRanks
Frequently Asked Questions About Oxford Biomedica
Does Oxford Biomedica hold EMA or MHRA GMP certificates?
CDMO Signal tracks 4 EMA and 8 MHRA GMP certificates for Oxford Biomedica.
How many clinical programs is Oxford Biomedica linked to?
Oxford Biomedica is associated with 7 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Oxford Biomedica's CDMO Signal Score?
Oxford Biomedica has a Signal Score of 76/100, based on quality, operations, financial stability, and capacity data.
Evaluating Oxford Biomedica for a manufacturing program?
Use the free AI matchmaker to compare Oxford Biomedica against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 81.0
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid
Andelyn Biosciences
Columbus, OH
Signal Score: 63.0
AAV, Lentiviral, Plasmid DNA
Ascend Advanced Therapies
London, United Kingdom
Signal Score: 78.1
AAV, Lentiviral, Plasmid
Advent Bioservices
London, United Kingdom
Signal Score: 78.1
AAV, Lentiviral, Adenoviral
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC